Make Better Decisions - Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

Get the Book: Make Better Decisions

Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

PDF eBook: Just $10 Get Print Book on Amazon

Serving leading biopharmaceutical companies globally:

McKinsey
Boehringer Ingelheim
Moodys
McKesson
Express Scripts
Johnson and Johnson

Last Updated: October 14, 2019

DrugPatentWatch Database Preview

CUBICIN Drug Profile

See Plans and Pricing

« Back to Dashboard

When do Cubicin patents expire, and what generic alternatives are available?

Cubicin is a drug marketed by Cubist Pharms Llc and is included in one NDA. There are two patents protecting this drug and two Paragraph IV challenges.

This drug has three patent family members in three countries.

The generic ingredient in CUBICIN is daptomycin. There are ten drug master file entries for this compound. Seventeen suppliers are listed for this compound. Additional details are available on the daptomycin profile page.

Drug patent expirations by year for CUBICIN
Drug Prices for CUBICIN

See drug prices for CUBICIN

Recent Clinical Trials for CUBICIN

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
Poitiers University HospitalPhase 3
University Hospital Inselspital, BernePhase 1
Cubist Pharmaceuticals LLCN/A

See all CUBICIN clinical trials

Recent Litigation for CUBICIN

Identify potential future generic entrants

District Court Litigation
Case NameDate
Cubist Pharmaceuticals LLC v. Crane Pharmaceuticals LLC2016-02-10
Cubist Pharmaceuticals LLC v. Sagent Pharmaceuticals, Inc.2015-12-17
Cubist Pharmaceuticals, Inc. v. Hospira, Inc.2014-12-19

See all CUBICIN litigation

PTAB Litigation
PetitionerDate
Fresenius Kabi USA LLC2015-07-10
Fresenius-Kabi USA LLC2014-11-03
Agila Specialties Inc.2014-10-24

See all CUBICIN litigation

Pharmacology for CUBICIN
Synonyms for CUBICIN
060D533
103060-53-3
2,2'-((3S,6S,9R,15S,18R,21S,24S)-30-((S)-2-((S)-4-amino-2-((S)-2-decanamido-3-(1H-indol-3-yl)propanamido)-4-oxobutanamido)-3-carboxypropanamido)-3-(2-(2-aminophenyl)-2-oxoethyl)-24-(3-amino
AB0012614
AB01274779_02
AB01274779-01
AKOS005146218
AKOS024457871
AKOS026750170
AKOS032949840
AN-5525
Antibiotic A-21978 C0
AOB87734
BC677644
C12013
C72H101N17O26
CHEBI:600103
CHEMBL387675
CHEMBL404822
Cidecin
CS-1857
Cubicin (TN)
Cubicin Rf
D01080
D4229
Dapcin
Daptomicina
Daptomicina [Spanish]
DAPTOMYCIN
Daptomycin (JAN/USAN/INN)
Daptomycin [USAN:INN:BAN]
Daptomycin for injection
Daptomycine
Daptomycine [French]
Daptomycinum
Daptomycinum [Latin]
DB00080
Deptomycin
DOAKLVKFURWEDJ-RWDRXURGSA-N
EX-A1967
HY-B0108
LS-171846
LY 146032
LY-146032
LY146032
MFCD08282794
MK-3009
MolPort-003-846-138
MolPort-023-276-990
MolPort-046-033-485
N-decanoyl-L-tryptophyl-L-asparaginyl-L-aspartyl-L-threonylglycyl-L-ornithyl-L-aspartyl-D-alanyl-L-aspartylglycyl-D-seryl-threo-3-methyl-L-glutamyl-3-anthraniloyl-L-alanine 1.13-3.4-lactone
N-decanoyl-L-tryptophyl-L-asparaginyl-L-aspartyl-L-threonylglycyl-L-ornithyl-L-aspartyl-D-alanyl-L-aspartylglycyl-D-seryl-threo-3-methyl-L-glutamyl-3-anthraniloyl-L-alanine epsilon(1)-lactone
N-Decanoyl-L-tryptophyl-L-asparaginyl-L-aspartyl-L-threonylglycyl-L-ornithyl-L-aspartyl-D-alanyl-L-aspartylglycyl-D-seryl-threo-3-methyl-L-glutamyl-3-anthraniloyl-L-alanine epsilon1-lactone
NCGC00346517-01
NCGC00346517-04
NWQ5N31VKK
propyl)-6-(1-carboxypropan-2-yl)-9-(hydroxymethyl)-18,31-dimethyl-2,5,8,11,14,17,20,23,26,29-decaoxo-1-oxa-4,7,10,13,16,19,22,25,28-nonaazacyclohentriacontane-15,21-diyl)diacetic acid
Q-200927
S-7668
s1373
SCHEMBL13491700
SCHEMBL1650768
SCHEMBL28102
SCHEMBL8221756
SR-01000872587
SR-01000872587-1
UNII-NWQ5N31VKK

US Patents and Regulatory Information for CUBICIN

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Cubist Pharms Llc CUBICIN daptomycin POWDER;INTRAVENOUS 021572-002 Sep 12, 2003 AP RX Yes Yes   See Pricing   See Pricing   See Pricing
Cubist Pharms Llc CUBICIN RF daptomycin POWDER;INTRAVENOUS 021572-003 Jul 6, 2016 RX Yes Yes   See Pricing   See Pricing   See Pricing
Cubist Pharms Llc CUBICIN daptomycin POWDER;IV (INFUSION) 021572-001 Sep 12, 2003 DISCN No No   See Pricing   See Pricing   See Pricing
Cubist Pharms Llc CUBICIN daptomycin POWDER;INTRAVENOUS 021572-002 Sep 12, 2003 AP RX Yes Yes   See Pricing   See Pricing   See Pricing
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Expired US Patents for CUBICIN

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Cubist Pharms Llc CUBICIN daptomycin POWDER;IV (INFUSION) 021572-001 Sep 12, 2003   See Pricing   See Pricing
Cubist Pharms Llc CUBICIN daptomycin POWDER;IV (INFUSION) 021572-001 Sep 12, 2003   See Pricing   See Pricing
Cubist Pharms Llc CUBICIN daptomycin POWDER;INTRAVENOUS 021572-002 Sep 12, 2003   See Pricing   See Pricing
Cubist Pharms Llc CUBICIN daptomycin POWDER;IV (INFUSION) 021572-001 Sep 12, 2003   See Pricing   See Pricing
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration
Paragraph IV (Patent) Challenges for CUBICIN
Drugname Dosage Strength RLD Date
➤ Subscribe For Injection 500 mg/vial ➤ Subscribe   See Pricing
➤ Subscribe For Injection 500 mg/vial ➤ Subscribe   See Pricing

Supplementary Protection Certificates for CUBICIN

Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
1115417 06C0022 France   See Pricing PRODUCT NAME: DAPTOMYCINE; REGISTRATION NO/DATE: EU/1/05/328/001-002 20060119
1115417 SPC/GB06/024 United Kingdom   See Pricing SUPPLEMENTARY PROTECTION CERTIFICATE NO SPC/GB06/024 GRANTED TO CUBIST PHARMACEUTICALS, INC IN RESPECT OF THE PRODUCT DAPTOMYCIN, THE GRANT OF WHICH WAS ADVERTISED IN JOURNAL NO 6162 DATED 27 JUNE 2007 HAS HAD ITS MAXIMUM PERIOD OF DURATION CORRECTED, SUBJECT TO THE PAYMENT OF THE PRESCRIBED FEES IT WILL EXPIRE ON 22 JANUARY 2021.
1115417 SZ 22/2006 Austria   See Pricing PRODUCT NAME: DAPTOMYCIN
1115417 22/2006 Austria   See Pricing PRODUCT NAME: DAPTOMYCIN; REGISTRATION NO/DATE: EU/1/05/328/001 UND 002 20060119
>Patent Number >Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

McKinsey
Johnson and Johnson
Colorcon
McKesson
Harvard Business School
Baxter

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.